Statement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval
(Source – www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following
Read More
WWP Twitch chat: New benefits eligibility for Veterans exposed to toxins
(Source – news.va.gov) If you have been exposed to a toxic substance during your military service, you may be eligible
Read MoreMedicare Advantage star ratings are failing to improve plan quality: Study
(By Jakob Emerson for Becker’s Hospital Review) The Medicare Advantage star rating system and its quality bonus payment program is
Read MoreWhat to know about the drug price fight in those TV ads
(By Arthur Allen for NPR) In recent months ominous ads about prescription drugs have flooded the TV airwaves. Perhaps by
Read MoreCMS Releases Revised Guidance for Historic Medicare Drug Price Negotiation Program
(Source – www.cms.gov/newsroom) For the first time in history, Medicare has the ability to directly negotiate the prices of covered
Read MoreMedicare Advantage profits could be under pressure in 2024, analysts say
(By Rylee Wilson for Becker’s Hospital Review) Medicare Advantage profits will likely be stable in 2023 but could face pressure
Read MoreWhy the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
(By Arthur Allen for KFF Health News) This week the FDA is expected to approve what many scientists and doctors
Read MoreCombatting PTSD with vital support for Veterans
(Source – news.va.gov) PTSD doesn’t discriminate. With PTSD, memories associated with traumatic events—like combat, sexual assault, accidents and even natural
Read MoreAfter ICU discharge, Alzheimer’s patients’ risk of dying doubles: Study
(By Bari Faye Dean for Becker’s Hospital Review) Older adults with Alzheimer’s disease and related dementia are twice as likely
Read MorePatients Squeezed in Fight Over Who Gets to Bill for Pricey Infusion Drugs
(By Samantha Liss for KFF Health News) Health insurers and medical providers are battling over who should supply high-cost infusion
Read More